Related Experiment Videos
Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?
Chuer Zhang1, Gladstone Austin Amos Burke2
1a School of Clinical Medicine , University of Cambridge , Cambridge , UK.
Insights
MYC-positive precursor B-acute lymphoblastic leukemia (ALL) is rare and presents diagnostic challenges. Current data is insufficient to guide treatment consensus for this pediatric cancer subgroup, necessitating further research.
Area of Science:
- Pediatric Oncology
- Hematologic Malignancies
- Molecular Diagnostics
Background:
- Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, with precursor B-cell ALL having >90% survival.
- Mature B-cell leukemia/lymphoma (Burkitt) requires intensive chemotherapy and Rituximab, achieving >95% survival.
- MYC translocation at 8q24 defines Burkitt leukemia/lymphoma.
Purpose of the Study:
- To systematically review the occurrence and treatment of MYC-positive precursor B-ALL.
- To identify diagnostic and treatment challenges in this rare ALL subpopulation.
- To highlight the need for focused research in MYC-positive precursor B-ALL.
Main Methods:
- Systematic literature review.
- Data extraction on MYC-positive precursor B-ALL cases.
- Analysis of reported treatments and outcomes between 1980 and 2016.
Main Results:
- MYC-positive precursor B-ALL represents a rare but distinct subgroup of pediatric ALL.
- A significant lack of data exists regarding optimal treatment strategies.
- Existing literature does not provide a consensus for managing these patients.
Conclusions:
- MYC-positive precursor B-ALL poses a diagnostic and therapeutic dilemma.
- Current evidence is inadequate to establish treatment guidelines.
- Focused research is crucial to improve outcomes for children with this specific leukemia subtype.
Abstract:
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Within ALL, precursor B-cell disease predominates and now has survival >90%. Mature B-cell, or Burkitt leukemia/lymphoma, is distinct from ALL and requires short intensive chemotherapy and with the addition of Rituximab, survival rates of >95% are achieved. Its defining characteristic is MYC translocation at 8q24. Patients who have features of both ALL and Burkitt leukemia/lymphoma represent a rare subpopulation of ALL and present a diagnostic and treatment conundrum. We have performed a systematic review on the occurrence of and treatment of MYC positive precursor B-ALL, reported between 1980 and 2016. The review highlighted a lack of data to guide any consensus about how to treat this important group of children and focused research in this area is needed.